Management of primary and advanced breast cancer in older unfit patients (medical treatment)

Cancer Treatment Reviews

Volumn 35, Issue 6, 2009, Pages 503-508

  Aapro, M ^a   Monfardini, Silvio ^b,c   Jirillo, Antonio ^b   Basso, Umberto ^b  

^a Multidisciplinary Oncology Institute   (Switzerland)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Adjuvant; Aromatase inhibitors; Breast cancer; Chemotherapy; Elderly; Endocrine therapy; Frail; Metastatic; Vulnerable

Indexed keywords

ANASTROZOLE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CITALOPRAM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; LETROZOLE; METHOTREXATE; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; STEROID; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VENLAFAXINE; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ADVANCED CANCER; ARTHRALGIA; BREAST CANCER; BREAST SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; COMORBIDITY; DELAYED DIAGNOSIS; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENDOMETRIUM CANCER; FRACTURE; FRAIL ELDERLY; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; MEDICAL DECISION MAKING; METASTASIS; MYALGIA; OSTEOPOROSIS; OVERALL SURVIVAL; PATIENT SAFETY; REVIEW; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION; UNSPECIFIED SIDE EFFECT; VAGINA DISCHARGE;

AGED; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DECISION MAKING; DIPHOSPHONATES; GERIATRIC ASSESSMENT; HUMANS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; OSTEOPOROSIS; TAMOXIFEN;

EID: 70349335347     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.04.002     Document Type: Review

References (60)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 58 (2008) 71-96
2. Héry C., Ferlay J., Boniol M., and Autier P. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol 19 (2008) 1009-1018
3. Bouchardy Bouchardy C., Rapiti E., Gerald F., et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 21 (2003) 3580-3587
4. Basso U., Brunello A., Pogliani C., and Monfardini S. Treatment options for early breast cancer in elderly women. Expert Rev Anticancer Ther 4 (2004) 197-211
5. Giordano S.H., Duan Z., Kuo Y.F., Hortobagyi G.N., and Goodwin J.S. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24 (2006) 2750-2756
6. Yancik R., Wesley M.N., Ries L.A., et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285 (2001) 885-892
7. Ries LAG, Harkins D, Krapcho M, et al. Cancer statistics review 1975_2003. Bethesda: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975_2003/ [accessed February 2009].
8. Balducci L., and Yates J. General guidelines for the management of older patients with cancer. Oncology (Huntingt) 14 (2000) 221-227
9. Basso U., Tonti S., Bassi C., et al. Management of frail and not-frail elderly cancer patients in a hospital-based geriatric oncology program. Crit Rev Oncol Hematol 66 (2008) 163-170
10. Exterman M., Meyer J., McGinnis M., et al. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol 49 (2004) 69-75
11. Aapro M.S., Köhne C.H., Cohen H.J., and Extermann M. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist 10 (2005) 198-204
12. Hind D., Wyld L., Beverley C.B., and Reed M.W. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev (2006) CD004272
13. Biganzoli L., Licitra S., Claudino W., Pestrin M., and Di Leo A. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients - a jungle?. Eur J Cancer 43 (2007) 2270-2278
14. Crivellari D., Price K., Gelber R.D., et al. International Breast Cancer Study Group. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV. J Clin Oncol 21 (2003) 4517-4523
15. Monfardini S., Brunello A., Molino A., et al. Comorbidity and choice of adjuvant endocrine therapy in breast cancer patients (pts) older than 70 years. Proc Am Soc Clin Oncol (2006) 24 [abstr. 8546]
16. Vandel P. Antidepressant drugs in the elderly - role of the cytochrome P450 2D6. World J Biol Psychiatr 4 (2003) 74-80
17. Goetz M.P., Rae J.M., Suman V.J., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23 (2005) 9312-9318
18. Jin Y., Desta Z., Stearns V., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97 (2005) 30-39
19. Lash T.L., Pedersen L., Cronin-Fenton D., et al. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer 99 (2008) 616-621
20. Eisen A., Trudeau M., Shelley W., Messersmith H., and Pritchard K.I. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat Rev 34 (2008) 157-174
21. Crivellari D., Sun Z., Coates A.S., et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 26 (2008) 1972-1979
22. Muss H.B., Tu D., Ingle J.N., et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 26 (2008) 1956-1964
23. Jonat W., Gnant M., Boccardo F., et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 7 (2006) 991-996
24. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 (2007) 559-570
25. Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., Baum M., Arimidex, Tamoxifen, and Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9 (2008) 45-53
26. Hadji P., Body J.J., Aapro M.S., et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19 (2008) 1407-1416
27. Extermann M., Balducci L., and Lyman G.H. What threshold for adjuvant therapy in older breast cancer patients?. J Clin Oncol 18 (2000) 1709-1717
28. www.adjuvantonline.com [accessed February 2009].
29. Brunello A., Basso U., Pogliani C., et al. Adjuvant chemotherapy for elderly patients (> or =70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients. Ann Oncol 16 (2005) 1276-1282
30. Clarke M., Coates A.S., Darby S.C., et al., Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 371 (2008) 29-40
31. Muss H.B., Berry D.L., Cirrincione C., et al. J Clin Oncol (2008) 26 [abstr. 507]
32. Crivellari D., Bonetti M., Castiglione-Gertsch M., et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 18 (2000) 1412-1422
33. Wildiers H., Kunkler I., Biganzoli L., et al. International Society of Geriatric Oncology. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 8 (2007) 1101-1115
34. Aapro M.S., Cameron D.A., Pettengell R., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42 (2006) 2433-2453
35. Dahabreh I.J., Linardou H., Siannis F., Fountzilas G., and Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 13 (2008) 620-630
36. Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemo therapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 (2007) 29-36
37. Clemens M, Kaufman JR, Mackey P, et al. Trastuzumab plus anastrozole may prolong overall survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer: results of a post-hoc analysis from the TAnDEM study. American Society of Clinical Oncology Breast Cancer Symposium; 2007 [abstr. 231].
38. Bertelli G., Garrone O., Merlano M., et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 69 6 (2005) 471-477
39. Bottini A., Generali D., Brizzi M.P., et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24 (2006) 3623-3628
40. Howell A., Robertson J.F., Quaresma Albano J., et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20 (2002) 3396-3403
41. Chia S., Gradishar W., Mauriac L., et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26 (2008) 1664-1670
42. McCormack P., and Sapunar F. Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer. Clin Breast Cancer 8 (2008) 347-351
43. Hamberg P., Verweij J., and Seynaeve C. Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy. Eur J Cancer 43 (2007) 1514-1528
44. Brunello A., Roma A., Falci C., and Basso U. Chemotherapy and targeted agents for elderly women with advanced breast cancer. Recent Pat Anti-Cancer Drug Discov 3 (2008) 187-201
45. Bajetta E., Procopio G., Celio L., et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 23 (2005) 2155-2161
46. Aapro M.S., Conte P., Esteban González E., and Trillet-Lenoir V. Oral vinorelbine: role in the management of metastatic breast cancer. Drugs 67 5 (2007) 657-667
47. Colleoni M., Rocca A., Sandri M.T., et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13 (2002) 73-80
48. Lonardi S., Bortolami A., Stefani M., and Monfardini S. Oral anticancer drugs in the elderly: an overview. Drugs Aging 24 5 (2007) 395-410
49. Durbecq V., Ameye L., Veys I., et al. A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristics. Crit Rev Oncol Hematol 67 (2008) 80-92
50. Bullock K., and Blackwell K. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. Oncologist 13 (2008) 515-525
51. Chan A.A. Review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. Ann Oncol 18 (2007) 1152-1158
52. Bartsch R., Wenzel C., Altorjai G., et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 25 (2007) 3853-3858
53. Fyfe G., Mass R., Murphy M., and Slamon D. Older (age >60) patients obtain survival benefit from herceptin plus chemotherapy. Eur J Cancer 37 (2001) S189
54. Brunello A., Monfardini S., Crivellari D., et al. Multicenter analysis of activity and safety of trastuzumab plus chemotherapy in advanced breast cancer in elderly women (>70 years). Proc Am Soc Clin Oncol (2008) 26 [abstr. 1096]
55. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99 (2007) 1232-1239
56. Pasetto L.M., Falci C., Sinigaglia G., and Monfardini S. Can bevacizumab be safely administered to all coorectal cancer (CRC) patients older than 70 years?. Ann Oncol (2006) 17S vi43
57. Body J.J., Coleman R., Clezardin P., Ripamonti C., Rizzoli R., and Aapro M. International Society of Geriatric Oncology. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 43 (2007) 852-858
58. Aapro M., Abrahamsson P.A., Body J.J., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19 (2008) 420-432
59. Basso U., and Monfardini S. Multidimensional geriatric evaluation in elderly cancer patients: a practical approach. Eur J Cancer Care (Engl) 13 (2004) 424-433
60. Monfardini S., Gridelli C., Pasetto L.M., Soubeyran P., Droz J.P., and Basso U. Vulnerable and frail elderly: an approach to the management of the main tumour types. Eur J Cancer 44 (2008) 488-493